Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATOLL: Letrozole Tolerability in Breast Cancer Patients Intolerant to Anastrozole
NCT00329940Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2005
- Primary completion
- Jan 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of letrozole in breast cancer, sponsored by Novartis. Primary endpoint: Rheumatological tolerability of letrozole at 6 months. Started Nov 2005; status: completed.
02
Drugs
letrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00329940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00329940.